Atrás
78
También listada como
TKPHF
OTC
Rango del Día
$17.79
$17.99
Rango de 52 Semanas
$12.99
$18.82
Volumen
3,227,688
Promedio 50D / 200D
$17.61
/
$15.40
Cierre Anterior
$17.83
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 0.5 | 0.4 |
| P/B | 0.0 | 2.9 |
| ROE % | 1.5 | 3.8 |
| Net Margin % | 2.4 | 3.9 |
| Rev Growth 5Y % | 9.4 | 10.0 |
| D/E | 0.7 | 0.2 |
Insider Trading Activity
8 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Lo Andrew Tak Shing
Senior Managing Director
|
grant | 227,637 | — | — |
| Feb 28, 2026 |
Lo Andrew Tak Shing
Senior Managing Director
|
other | 66,848 | — | — |
| Feb 2, 2026 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 15,000 | — | — |
| Jan 26, 2026 |
Tak Paul Peter
Chief Executive Officer
|
grant | 629,000 | — | — |
| Aug 4, 2025 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 30,000 | — | — |
| Jun 25, 2025 |
Tak Paul Peter
Chief Executive Officer
|
grant | 42,826 | $4.67 | $199,997 |
| Jun 24, 2025 |
YU Wing Tak Wendy
Director
|
grant | 20,000 | — | — |
| May 5, 2025 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 15,000 | — | — |
Puntos Clave
Revenue grew 9.41% annually over 5 years — modest growth
Earnings declined -25.08% over the past year
ROE of 1.52% is below average
Generating 856.39B in free cash flow
P/E of 0.52 — trading at a low valuation
Cash machine — converts 793.48% of earnings into free cash flow
Crecimiento
Revenue Growth (5Y)
9.41%
Revenue (1Y)7.45%
Earnings (1Y)-25.08%
FCF Growth (3Y)57.90%
Calidad
Return on Equity
1.52%
ROIC2.24%
Net Margin2.36%
Op. Margin7.48%
Seguridad
Debt / Equity
0.65
Current Ratio1.01
Interest Coverage2.50
Valoración
P/E Ratio
0.52
P/B Ratio0.01
EV/EBITDA12.22
Dividend Yield0.04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7.45% | Revenue Growth (3Y) | 6.66% |
| Earnings Growth (1Y) | -25.08% | Earnings Growth (3Y) | -41.65% |
| Revenue Growth (5Y) | 9.41% | Earnings Growth (5Y) | -26.80% |
| Profitability | |||
| Revenue (TTM) | 4.58T | Net Income (TTM) | 107.93B |
| ROE | 1.52% | ROA | 0.76% |
| Gross Margin | 65.51% | Operating Margin | 7.48% |
| Net Margin | 2.36% | Free Cash Flow (TTM) | 856.39B |
| ROIC | 2.24% | FCF Growth (3Y) | 57.90% |
| Safety | |||
| Debt / Equity | 0.65 | Current Ratio | 1.01 |
| Interest Coverage | 2.50 | Dividend Yield | 0.04% |
| Valuation | |||
| P/E Ratio | 0.52 | P/B Ratio | 0.01 |
| P/S Ratio | 0.01 | PEG Ratio | -2.57 |
| EV/EBITDA | 12.22 | Dividend Yield | 0.04% |
| Market Cap | 56.42B | Enterprise Value | 4.19T |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T |
| Net Income | 107.93B | 144.07B | 317.02B | 230.06B | 376.01B |
| EPS (Diluted) | 33.62 | 45.58 | 100.97 | 72.94 | 119.48 |
| Gross Profit | 3.00T | 2.83T | 2.78T | 2.46T | 2.20T |
| Operating Income | 342.59B | 214.08B | 490.51B | 460.84B | 509.27B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T |
| Total Liabilities | 7.31T | 7.83T | 7.60T | 7.49T | 7.74T |
| Shareholders' Equity | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T |
| Total Debt | 4.52T | 4.84T | 4.38T | 4.35T | 4.64T |
| Cash & Equivalents | 385.11B | 457.80B | 533.53B | 849.70B | 966.22B |
| Current Assets | 2.52T | 2.56T | 2.40T | 2.59T | 2.71T |
| Current Liabilities | 2.51T | 2.31T | 2.48T | 2.15T | 1.77T |
Puntuaciones de Estrategias
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#44 of 1024
Actividad Reciente
Entró
Cash Flow Compounder
Mar 24, 2026